Regeneron stock: 19.91 times earnings trails Vertex at 30.72

Published on 10/23/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 4.29 billion, up 16.70 percent year over year. Regeneron stock costs EUR 722.65 on October 23, 2026, below EUR 738.20 high.

Valuation and reporting date

Regeneron was valued at 19.91 times earnings on October 23, 2026.
Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
Regeneron stock costs EUR 722.65 at Lang & Schwarz on October 23, 2026 at 3:41 p.m. CEST.
Third-quarter results are scheduled for October 30, 2026 before the U.S. market opens.

Aquarellmalerei eines modernen Forschungscampus mit Glastürmen am Flussufer — Regeneron Pharma US75886F1075 präsentiert eine stimmungsvolle Aquarell-Ansicht eines modernen Forschungscampus entlang eines ruhigen Flussufers, Illustration mit AI erstellt.

Regeneron stock was valued at 19.91 times earnings on October 23, 2026, while Vertex Pharmaceuticals stood at 30.72 times earnings. The valuation comparison gives investors a measurable way to frame the biotechnology company ahead of its next report.

Revenue growth remains substantial

Regeneron generated USD 4.29 billion in revenue during the second quarter of 2026, up 16.70 percent from the same quarter of 2025. Net income attributable to common shareholders reached USD 1.30 billion, while diluted earnings per share were USD 12.23. MarketBeat reported that the prior quarterly revenue figure exceeded the USD 3.82 billion consensus estimate.

Stock stays below its yearly high

At Lang & Schwarz, Regeneron was trading at EUR 722.65 on October 23, 2026 at 3:41 p.m. CEST. The euro quotation stood below the EUR 738.20 52-week high and above the EUR 493.90 low reported for the same German market quotation. The primary Nasdaq quotation was USD 806.22 at 10:00 a.m. ET on October 23, 2026, with a market capitalization of USD 83.0 billion.

Valuation meets an October 30 date

The valuation remains below the 42.93 times earnings reported for Eli Lilly, whose market capitalization was USD 1.2 trillion at the same market snapshot. Regeneron's lower multiple sits alongside a 30.00 percent operating margin in the second quarter of 2026, according to the standardized quarterly figures.

Regeneron announced on September 24, 2026 that it will publish third-quarter 2026 financial and operating results on October 30, 2026 before the U.S. financial markets open. The company scheduled its conference call for 8:30 a.m. ET.

Comparison with peers

Regeneron: P/E 19.91, market capitalization USD 83.0 billion.

Eli Lilly: P/E 42.93, market capitalization USD 1.2 trillion.

Vertex Pharmaceuticals: P/E 30.72, market capitalization USD 133.1 billion.

Price position sets the frame

The contrast between Regeneron's 19.91 times earnings and the higher peer multiples places the upcoming report at the center of the stock's valuation discussion. Revenue growth of 16.70 percent in the second quarter provides the latest operating benchmark.

Regeneron was trading at EUR 722.65 at Lang & Schwarz on October 23, 2026 at 3:41 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.